These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12433608)

  • 1. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer.
    Tanaka T; Kawai Y; Kanai M; Taki Y; Nakamoto Y; Takabayashi A
    Am J Surg; 2002 Nov; 184(5):433-6. PubMed ID: 12433608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer.
    Sasaki K; Kawasaki H; Sato M; Koyama K; Yoshimi F; Nagai H
    Dig Surg; 2017; 34(1):60-67. PubMed ID: 27454870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Hu C; King TM; Chiu YL; Wang JH; Liu RS
    Cancer Biother Radiopharm; 2013; 28(6):479-87. PubMed ID: 23713869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of FDG-PET/CT in Colorectal Peritoneal Carcinomatosis: Potential Tool for Evaluation of Chemotherapeutic Response.
    Liberale G; Lecocq C; Garcia C; Muylle K; Covas A; Deleporte A; Hendlisz A; Bouazza F; El Nakadi I; Flamen P
    Anticancer Res; 2017 Feb; 37(2):929-934. PubMed ID: 28179354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U; You J; McSweeney S; Freeman M; Hendler A
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
    Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
    Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
    Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
    Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography.
    Ogunbiyi OA; Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Birnbaum EH; Fleshman JW; Read TE; Philpott GW; Kodner IJ
    Ann Surg Oncol; 1997 Dec; 4(8):613-20. PubMed ID: 9416407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (18)F-FDG PET/CT, cytoreductive surgery and intraperitoneal chemohyperthermia for the therapeutic management in peritoneal carcinomatosis: A pilot study.
    Cistaro A; Cucinotta M; Cassalia L; Priola A; Priola S; Pappalardo M; Coppolino P; De Simone M; Quartuccio N
    Rev Esp Med Nucl Imagen Mol; 2016; 35(4):232-7. PubMed ID: 26907833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
    Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of 18F-FDG PET in the detection of peritoneal carcinomatosis.
    Suzuki A; Kawano T; Takahashi N; Lee J; Nakagami Y; Miyagi E; Hirahara F; Togo S; Shimada H; Inoue T
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1413-20. PubMed ID: 15205922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E; Soydal C; Araz M; Aras G
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.
    Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE
    Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.